Designing lifesaving products for and with global markets

Propelevate is excited about our partnership with Vivacelle Bio, a biotechnology company, to drive a Sub-Saharan Africa strategy, which is fully integrated into its Series B financing round. 

Propelevate will leverage our experience expanding access to women’s health products around the world, ensuring that Vivacelle Bio’s innovations are designed for and with Sub-Saharan African health care providers and users, and that products are available within regional markets quickly.  

Vivacelle Bio is developing novel treatments for hypovolemia, a lack of effective circulating blood volume.  The use cases for these products are broad, with the potential to dramatically improve the outcome of neonatal sepsis and postpartum hemorrhage, and hypovolemia related to pneumonia, diarrheal disease and malaria.  

The successful phase IIA trial results for the treatment of septic shock were just published in the Lancet, which showed a 7X improvement in survivability of septic shock. In Sub-Saharan Africa, among birthing people, newborns and children under five with access to skilled health workers, this translates to more than 600,000 lives saved and significant progress on Sustainable Development Goal 3. In the region this will: 

• Cut maternal mortality from 511 to 437 per 100,000 live births;

• Cut neonatal mortality from 27 to 19 per 1,000 live births; and 

• Cut under-five mortality from 73 to 69.5 per 1,000 live births.